Zacks Research Weighs in on West Pharmaceutical Services, Inc.’s Q3 2024 Earnings (NYSE:WST)

West Pharmaceutical Services, Inc. (NYSE:WST) – Equities researchers at Zacks Research issued their Q3 2024 earnings estimates for West Pharmaceutical Services in a research report issued on Wednesday, October 2nd. Zacks Research analyst I. Bandyopadhyay expects that the medical instruments supplier will earn $1.51 per share for the quarter. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.42 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ FY2024 earnings at $6.42 EPS, Q4 2025 earnings at $2.25 EPS, Q1 2026 earnings at $1.89 EPS and Q2 2026 earnings at $2.15 EPS.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s revenue was down 6.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.11 EPS.

West Pharmaceutical Services Price Performance

WST opened at $296.50 on Monday. West Pharmaceutical Services has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. The firm has a market cap of $21.51 billion, a price-to-earnings ratio of 39.12, a PEG ratio of 10.69 and a beta of 1.01. The company has a fifty day simple moving average of $301.39 and a 200 day simple moving average of $332.11.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the sale, the vice president now directly owns 1,478 shares in the company, valued at $443,400. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.53% of the company’s stock.

Hedge Funds Weigh In On West Pharmaceutical Services

Several large investors have recently bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new position in shares of West Pharmaceutical Services in the first quarter worth approximately $27,000. Crewe Advisors LLC lifted its stake in West Pharmaceutical Services by 322.7% in the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 71 shares during the last quarter. Quarry LP raised its position in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the period. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $40,000. Finally, Northwest Investment Counselors LLC bought a new position in shares of West Pharmaceutical Services in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.